<DOC>
	<DOC>NCT01070927</DOC>
	<brief_summary>This study will evaluate the anti-tumour activity, safety and tolerability of RO4929097 as monotherapy in patients with recurrent or refractory non-small cell lung cancer. Patients will receive oral doses of RO4929097 of 80mg (cohort 1) or recommended Phase II dose (cohort 2) on a 3 days on 4 days off schedule. Anticipated time on study treatment is until disease progression or unacceptable toxicity. Target sample size is &lt;50.</brief_summary>
	<brief_title>An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>adult patients, &gt;/= 18 years of age stage IIIB/IV recurrent or refractory nonsmall cell lung cancer at most 2 lines of prior therapy in the metastatic setting (first line: platinum containing regimen and bevacizumab; second line: EGFRtargeted therapy) ECOG performance status 02 adequate liver, renal and bone marrow function prior chemotherapy or radiotherapy &lt;/= 4 weeks before first dose of study drug history of other malignancy within the past 2 years, except for basal cell skin carcinoma or in situ cervical carcinoma history of CNS metastases or leptomeningeal metastases, except for clinically stable disease serious cardiovascular illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>